Figure 2

Associations between the changes in the cytomegalovirus/Epstein-Barr virus (CMV/EBV) and media-alone immune response signatures from baseline to 21 to 24 weeks and clinical response to initial disease-modifying antirheumatic drug (DMARD) therapy among 43 patients with early rheumatoid arthritis. Shown are box plots representing the distributions of the changes from baseline to 21 to 24 weeks in (A) the CMV/EBV PCA-1 scores and (B) the media-alone PCA-2 scores, comparing responders and non-responders. Clinical response was defined as a decrease in the DAS28 ≥1.2 from baseline to 21 to 24 weeks. The horizontal dotted lines represent the medians. PCA, principal components analysis; DAS28, Disease Activity Score using 28 joints.